KIADIS PHARMA N V ORD NETHERLAND (OTCMKTS:KIADF)’s Trend Up, Especially After Decreased Shorts
January 23, 2018 - By Marie Mckinney
The stock of KIADIS PHARMA N V ORD NETHERLAND (OTCMKTS:KIADF) registered a decrease of 0.28% in short interest. KIADF’s total short interest was 72,400 shares in January as published by FINRA. Its down 0.28% from 72,600 shares, reported previously.
It closed at $9.86 lastly. It is down 0.00% since January 23, 2017 and is . It has underperformed by 16.70% the S&P500.
Kiadis Pharma N.V., a clinical stage biopharmaceutical company, focuses on the research and development of cell immunotherapy products for the treatment of blood cancers and inherited blood disorders in the Netherlands. The company has market cap of $183.51 million. The firm focuses on therapeutic indications, including leukaemia, a common form of blood cancer; and thalassemia, an inherited blood disorder. It currently has negative earnings. The Company’s products comprise ATIR101 , a Phase II clinical trial product, which addresses the risk and limitations of hematopoietic stem cell transplantation in blood cancer; and ATIR201, which is in Phase I/II clinical development for inherited blood disorders with an initial focus on thalassemia.
More notable recent Kiadis Pharma N.V. (OTCMKTS:KIADF) news were published by: Businesswire.com which released: “Kiadis Pharma Raises €5 Million in Private Placement with Institutional Investors” on June 13, 2017, also Businesswire.com with their article: “Kiadis Pharma to Present at Biotech Showcaseâ„¢ Annual Conference on January 8 …” published on January 05, 2018, Businesswire.com published: “Kiadis Pharma proposes former Cipla CEO Subhanu Saxena as new Supervisory …” on January 16, 2018. More interesting news about Kiadis Pharma N.V. (OTCMKTS:KIADF) were released by: Globenewswire.com and their article: “Kiadis to Host Key Opinion Leader Meeting on Addressing the Risks of …” published on May 22, 2017 as well as Businesswire.com‘s news article titled: “Kiadis Pharma appoints Dr. Andrew Sandler as Chief Medical Officer” with publication date: September 29, 2017.
Kiadis Pharma N.V.-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.